Optimisation of microculture methods for quantitation of HIV from plasma and cellular fractions of peripheral blood. NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Optimisation of microculture methods for quantitation of HIV from plasma and cellular fractions of peripheral blood.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:100 (poster no. 50). Unique Identifier : AIDSLINE ASHM5/94348911
Dunne A; Crowe S; Macfarlane Burnet Centre for Medical Research, Fairfield; Hospital, Victoria.

Abstract: OBJECTIVE: Quantitation of HIV in plasma and PBMCs is used in clinical trials to follow disease progression and determine drug efficacy. We have modified the ACTG protocols to reduce cost and optimise virus isolation. METHODS: Microculture procedures as described by the AIDS Clinical Trials Group (ACTG) have been used as the basis for these procedures. To date we have compared concentrations of PHA and IL-2 used for stimulation of donor cells, number of days of stimulation of donor cells, use of donor cells from single or multiple donors, and methods of isolation and storage of cells and plasma from HIV-infected individuals. RESULTS: compared to the ACTG procedures, our preliminary data suggest that it is feasible to use stimulation medium for donor cells that has no IL-2 and less foetal calf serum, donor cells need only to be stimulated for as little as 30 hours before use in HIV culture, a less expensive freezing medium for storage of HIV-infected cells provides better recovery, and that manipulations of microcultures can be reduced to a minimum with no effect on the outcome of the assay. CONCLUSIONS: The ACTG protocol can be modified to be more cost effective and less time consuming.
Keywords: Cost-Benefit Analysis Human HIV/*ISOLATION & PURIF HIV Infections/*MICROBIOLOGY Viremia/*MICROBIOLOGY *Virus Cultivation/ECONOMICS ABSTRACTKWDcost-benefitanalysishumanhiv/KWDisolation&purifhivinfections/KWDmicrobiologyviremia/KWDmicrobiologyKWDviruscultivation/economicsabstract
941230
M94C4316

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .